Ragunath Singaravelu

Ottawa Hospital — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index1.7kcitations52works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(14), SARS-CoV-2 and COVID-19 Research(12), Virus-based gene therapy research(11), Hepatitis C virus research(10), interferon and immune responses(8)

Publications52 total

Oncolytic vaccinia virus encoding constitutively active EPAC remodels the tumor microenvironment to enhance therapeutic efficacy with chemotherapy and surgery
Journal for ImmunoTherapy of Cancer·2026Open Access
RNAi Screening in Tumor Cells Identifies Artificial microRNAs That Improve Oncolytic Virus Replication
Pharmaceuticals·2025Open Access
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic viruses
Nature Biomedical Engineering·2024· 5 cited
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
Molecular Therapy — Methods & Clinical Development·2023· 11 citedOpen Access
Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies
Nature Communications·2023· 29 citedOpen Access
Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development
Journal of Biological Chemistry·2023· 5 citedOpen Access
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX
Frontiers in Immunology·2023· 12 citedOpen Access
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
Molecular Therapy·2022· 6 citedOpen Access
Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
Nature Communications·2022· 46 citedOpen Access
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
Molecular Therapy·2021· 23 citedOpen Access
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern
ACS Infectious Diseases·2021· 24 cited
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
Journal of Visualized Experiments·2021
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
Journal of Visualized Experiments·2021· 2 cited
Oncolytic Viruses
2021
A High-Throughput NanoBiT-Based Serological Assay Detects SARS-CoV-2 Seroconversion
Nanomaterials·2021· 11 citedOpen Access
SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
Biosensors and Bioelectronics·2021· 32 citedOpen Access
Characterization of Critical Determinants of ACE2–SARS CoV-2 RBD Interaction
International Journal of Molecular Sciences·2021· 32 citedOpen Access
Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
Molecular Therapy·2021· 26 citedOpen Access
Characterization of Critical Determinants of ACE2-RBD Interaction
2021Open Access
Profiling of MicroRNA Targets Using Activity-Based Protein Profiling: Linking Enzyme Activity to MicroRNA-185 Function
Cell chemical biology·2021· 14 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

John Paul Pezacki(25), John C. Bell(21), Taha Azad(18), Carolina S. Ilkow(18), Stephen Boulton(16), Mathieu J. F. Crupi(15), Reza Rezaei(14), Adrian Pelin(13), Jean‐Simon Diallo(13), Julia Petryk(12), Zaid Taha(12), Rodney K. Lyn(11), Joanna Poutou(11), Taylor R. Jamieson(11), Bradley Austin(9), Nikolas T. Martin(9), Abera Surendran(8), Prashanth Srinivasan(7), Rodney S. Russell(7), Jaahnavi Dave(7)